Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS
Healthcare Corporation (VITAS), the nation’s largest provider of
end-of-life care, and Roto-Rooter, the nation’s largest commercial
and residential plumbing and drain cleaning services provider,
reported financial results for its first quarter ended March 31,
2011, versus the comparable prior-year period, as follows:
Consolidated operating results:
- Revenue increased 7.2% to $331
million
- GAAP Diluted EPS $0.84 equal to prior
year
- Adjusted EPS increased 12.6% to
$1.07
VITAS segment operating results:
- Net Patient Revenue of $236 million, an
increase of 5.7%
- Average Daily Census (ADC) of 12,919,
an increase of 4.8%
- Admissions of 15,798, an increase of
6.4%
- Net Income of $18.1 million, a decline
of 1.7%
- Adjusted EBITDA of $33.2 million, an
increase of 1.4%
- Adjusted EBITDA margin of 14.1%, a
decrease of 60 basis points
Roto-Rooter segment operating results:
- Revenue of $95.2 million, an increase
of 10.9%
- Job count of 179,716, an increase of
5.8%
- Net Income of $8.5 million, an increase
of 8.9%
- Adjusted EBITDA of $15.6 million, an
increase of 13.8%
- Adjusted EBITDA margin of 16.4%, an
increase of 42 basis points
VITAS
Net revenue for VITAS was $236 million in the first quarter of
2011, which is an increase of 5.7% over the prior-year period. Both
periods include revenue from the reversal of Medicare Cap accruals.
Excluding this impact of Medicare Cap, revenue increased 6.1%. This
revenue growth was the result of increased ADC of 4.8%, driven by
an increase in admissions of 6.4%, combined with Medicare price
increases of approximately 2.1%. This growth was partially offset
by geographic and level of acuity mix shift of the patient
base.
Average revenue per patient per day in the quarter, excluding
the impact of Medicare Cap, was $201.82, which is 1.2% above the
prior-year period. Routine home care reimbursement and high acuity
care averaged $157.93 and $696.25, respectively, per patient per
day in the first quarter of 2011. During the quarter, high acuity
days of care were 8.2% of total days of care, 35 basis points lower
than the prior-year quarter.
In the first quarter of 2011, VITAS recorded a positive revenue
adjustment of $1.0 million due to the reversal of estimated
Medicare Cap billing limitations recorded in prior periods. This
compares with a similar adjustment of $1.7 million for reversal of
Medicare Cap recorded in the first quarter of 2010. The reversal of
these Medicare Cap liabilities relates predominantly to VITAS’
largest Medicare provider number.
Of VITAS’ 33 unique Medicare provider numbers, 31 provider
numbers, or 94%, have a Medicare Cap cushion of 15% or greater for
the current Medicare Cap period. One provider has a Medicare Cap of
5% and one small program has a modest Medicare Cap liability. VITAS
generated an aggregate Medicare Cap cushion of $223 million,
or 26%, during the trailing twelve-month period.
The first quarter of 2011 gross margin, excluding the impact of
Medicare Cap, was 21.5%, which is a decline of 74 basis points from
the first quarter of 2010. This decline in margin is a result of
increased costs related to the newly mandated physician visit for
recertification, expansion of our community liaison program as well
as costs associated with our continued expansion of inpatient
units.
Selling, general and administrative expense was $18.7 million in
the first quarter of 2011, which is an increase of 3.1% when
compared to the prior-year quarter. Adjusted EBITDA totaled
$33.2 million in the quarter, an increase of 1.4% over the
prior-year period. Adjusted EBITDA margin, excluding the impact
from Medicare Cap, was 13.7% in the quarter which was 30 basis
points below the prior-year quarter.
Roto-Rooter
Roto-Rooter’s plumbing and drain cleaning business generated
sales of $95.2 million for the first quarter of 2011, an increase
of 10.9% over the prior-year quarter. Roto-Rooter’s gross margin
was 44.2% in the quarter, a 103 basis point decline when compared
to the first quarter of 2010. Adjusted EBITDA in the first quarter
of 2011 totaled $15.6 million, an increase of 13.8%, and the
Adjusted EBITDA margin was 16.4% in the quarter, an increase of 42
basis points, when compared to the prior-year quarter.
Job count in the first quarter of 2011 increased 5.8% when
compared to the prior-year period. During the first quarter of
2011, total residential jobs increased 4.7%, as residential
plumbing jobs increased 5.4% and residential drain cleaning jobs
increased 4.5%, when compared to the first quarter of 2010.
Residential jobs represented 72% of total job count in the quarter.
Total commercial jobs increased 8.7%, with commercial
plumbing/excavation job count increasing 10.2% and commercial drain
cleaning increasing 8.1% when compared to the prior-year quarter.
The “All Other” residential and commercial job category increased
3.6%.
Roto-Rooter continues to have periodic discussions with existing
franchisees to acquire franchise territories. Management will be
highly disciplined in terms of valuation, risk assessment and
overall return on investment of any potential acquisition. The
timing or actual completion of any acquisition cannot be
predicted.
Chemed Consolidated Debt
and Cash Flows
Chemed had total debt of $161 million at March 31, 2011. This
debt is net of the discount taken as a result of convertible debt
accounting requirements. Excluding this discount, aggregate debt is
$187 million and is due in May 2014. Chemed’s total debt
equates to less than one times trailing twelve-month adjusted
EBITDA.
In March 2011 Chemed replaced its existing credit facility with
a new Credit Agreement. Terms of this Credit Agreement consist of a
five-year $350 million revolving credit facility. The interest rate
on this Credit Agreement has a floating rate that is currently
LIBOR plus 175 basis points. This Credit Agreement provides Chemed
with increased flexibility in terms of acquisitions, share
repurchases, dividends and other corporate needs. In addition, an
expansion feature is included in this facility that provides Chemed
the opportunity to increase its revolver and/or enter into term
loans for an additional $150 million. At March 31, 2011, this
credit facility had approximately $322 million of undrawn borrowing
capacity after deducting $28 million for letters of credit issued
under this facility to secure the Company’s workers’ compensation
insurance.
Capital expenditures for the first quarter of 2011 aggregated
$6.2 million and compared favorably to depreciation and
amortization during the same period of $7.3 million.
The Company increased its quarterly dividend per share in the
third quarter of 2010, from $0.12 per share to $0.14 per share. The
company purchased $96.3 million of treasury stock in the fourth
quarter of 2010 and an additional $21.8 million in the first
quarter of 2011. Total shares repurchased in the first quarter of
2011 totaled 341,513. Approximately $97.4 million is remaining
under Chemed’s previously announced share repurchase program.
Management will continually evaluate cash utilization alternatives,
including share repurchase, debt repurchase, acquisitions and
increased dividends to determine the most beneficial use of
available capital resources.
Guidance for
2011
VITAS expects to achieve full-year 2011 revenue growth, prior to
Medicare Cap, of 7% to 9%. Admissions in 2011 are estimated to
increase 5% to 7% and full-year Adjusted EBITDA margin, prior to
Medicare Cap, is estimated to be 15.3% to 16.3%. Effective
October 1, 2010, Medicare increased the average hospice
reimbursement rates by approximately 2.1%. Consistent with prior
years, our guidance assumes VITAS will incur an additional $3.7
million of estimated Medicare contractual billing limitations for
the remainder of 2011.
Roto-Rooter expects to achieve full-year 2011 revenue growth of
5% to 8%. The revenue estimate is a result of increased pricing of
approximately 3.0%, a favorable mix shift to higher revenue jobs,
with job count growth estimated at 0% to 3%. Adjusted EBITDA margin
for 2011 is estimated in the range of 16.5% to 17.5%.
Based upon the above metrics, an effective tax rate of 39.0% and
a full-year average diluted share count of 21.6 million, management
estimates 2011 earnings per diluted share, excluding non-cash
expense for stock options, the non-cash interest expense related to
the accounting for convertible debt and other items not indicative
of ongoing operations will be in the range of $4.65 to $4.85. This
compares to Chemed’s 2010 adjusted earnings per diluted share of
$4.17.
Conference
Call
Chemed will host a conference call and webcast at 10 a.m., ET,
on Tuesday, April 26, 2011, to discuss the Company's quarterly
results and to provide an update on its business. The dial-in
number for the conference call is (800) 510-0178 for U.S. and
Canadian participants and (617) 614-3450 for international
participants. The participant passcode is 43461477. A live webcast
of the call can be accessed on Chemed's website at www.chemed.com by clicking on Investor Relations
Home.
A taped replay of the conference call will be available
beginning approximately 24 hours after the call's conclusion. It
can be accessed by dialing (888) 286-8010 for U.S. and Canadian
callers and (617) 801-6888 for international callers and will be
available for one week following the live call. The replay passcode
is 97719698. An archived webcast will also be available at
www.chemed.com.
Chemed Corporation operates in the healthcare field through its
VITAS Healthcare Corporation subsidiary. VITAS provides daily
hospice services to approximately 13,000 patients with severe,
life-limiting illnesses. This type of care is focused on making the
terminally ill patient's final days as comfortable and pain-free as
possible.
Chemed operates in the residential and commercial plumbing and
drain cleaning industry under the brand name Roto-Rooter.
Roto-Rooter provides plumbing and drain service through
company-owned branches, independent contractors and franchisees in
the United States and Canada. Roto-Rooter also has licensed master
franchisees in Indonesia, Singapore, Japan, and the
Philippines.
This press release contains information about Chemed’s EBITDA,
Adjusted EBITDA and Adjusted Diluted EPS, which are not measures
derived in accordance with GAAP and which exclude components that
are important to understanding Chemed’s financial performance. In
reporting its operating results, Chemed provides EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS measures to help investors and
others evaluate the Company’s operating results, compare its
operating performance with that of similar companies that have
different capital structures and evaluate its ability to meet its
future debt service, capital expenditures and working capital
requirements. Chemed’s management similarly uses EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS to assist it in evaluating the
performance of the Company across fiscal periods and in assessing
how its performance compares to its peer companies. These measures
also help Chemed’s management to estimate the resources required to
meet Chemed’s future financial obligations and expenditures.
Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should
not be considered in isolation or as a substitute for comparable
measures calculated and presented in accordance with GAAP. We
calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by
service revenue and sales. A reconciliation of Chemed’s net income
to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is
presented in the tables following the text of this press
release.
Forward-Looking
Statements
Certain statements contained in this press release and the
accompanying tables are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "believe," "expect," "hope," "anticipate," "plan" and
similar expressions identify forward-looking statements, which
speak only as of the date the statement was made. Chemed does not
undertake and specifically disclaims any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. These
statements are based on current expectations and assumptions and
involve various risks and uncertainties, which could cause Chemed's
actual results to differ from those expressed in such
forward-looking statements. These risks and uncertainties arise
from, among other things, possible changes in regulations governing
the hospice care or plumbing and drain cleaning industries;
periodic changes in reimbursement levels and procedures under
Medicare and Medicaid programs; difficulties predicting patient
length of stay and estimating potential Medicare reimbursement
obligations; challenges inherent in Chemed's growth strategy; the
current shortage of qualified nurses, other healthcare
professionals and licensed plumbing and drain cleaning technicians;
Chemed’s dependence on patient referral sources; and other factors
detailed under the caption "Description of Business by Segment" or
"Risk Factors" in Chemed’s most recent report on form 10-Q or 10-K
and its other filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on such
forward-looking statements and there are no assurances that the
matters contained in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENT OF INCOME (in thousands, except per
share data)(unaudited)
Three Months Ended March 31,
2011 2010
Service revenues and sales
$ 330,918 $ 308,813
Cost of services provided and goods sold
237,458
219,137 Selling, general and administrative expenses (aa)
55,654 48,538 Depreciation
6,288 5,469 Amortization
970 1,224 Total costs and
expenses
300,370 274,368 Income
from operations
30,548 34,445 Interest expense
(3,244
) (2,952 ) Other income/(expense)--net (bb)
2,102 186 Income before income taxes
29,406 31,679 Income taxes
(11,305 )
(12,321 ) Net income
$ 18,101 $ 19,358
Earnings Per Share Net income
$
0.86 $ 0.86 Average number of shares
outstanding
21,055 22,593
Diluted Earnings Per Share Net income
$ 0.84
$ 0.84 Average number of shares outstanding
21,568 23,021 (aa)
Selling, general and administrative ("SG&A") expenses comprise
(in thousands): Three Months Ended March 31,
2011 2010
SG&A expenses before long-term incentive compensation and the
impact of market value gains of deferred compensation plans
$ 50,578 $ 48,350 Long-term incentive compensation
3,012 - Market value gains on assets held in deferred
compensation trusts
2,064 188
Total SG&A expenses
$ 55,654 $ 48,538
(bb) Other income/(expense)--net comprises (in
thousands): Three Months Ended March 31,
2011 2010 Market
value on assets held in deferred compensation trusts
$
2,064 $ 188 Interest income
61 75 Loss on disposal of
property and equipment
(21 ) (94 ) Other
(2 ) 17 Total other
income/(expense)--net
$ 2,102 $ 186
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEET (in thousands, except per share
data)(unaudited)
March 31,
2011 2010
Assets Current assets Cash and cash equivalents
$
59,745 $ 112,119 Accounts receivable less allowances
92,912 87,412 Inventories
7,967 7,609 Current
deferred income taxes
13,352 15,008 Prepaid expenses
9,538 9,886 Total current assets
183,514 232,034 Investments of deferred compensation plans
held in trust
31,897 25,925 Properties and equipment, at
cost less accumulated depreciation
79,146 75,189
Identifiable intangible assets less accumulated amortization
56,061 57,239 Goodwill
458,434 450,149 Other assets
13,676 13,692 Total Assets
$ 822,728 $ 854,228
Liabilities Current liabilities Accounts payable
$
38,249 $ 49,844 Income taxes
8,250 12,150 Accrued
insurance
35,511 34,478 Accrued compensation
39,469
37,613 Other current liabilities
14,457
12,439 Total current liabilities
135,936 146,524
Deferred income taxes
24,164 24,969 Long-term debt
161,054 153,853 Deferred compensation liabilities
31,437 25,522 Other liabilities
6,267
5,374 Total Liabilities
358,858
356,242
Stockholders' Equity Capital stock
30,709 30,087 Paid-in capital
379,167 343,967
Retained earnings
488,439 419,985 Treasury stock, at cost
(436,427 ) (298,031 ) Deferred compensation payable
in Company stock
1,982 1,978
Total Stockholders' Equity
463,870
497,986 Total Liabilities and Stockholders' Equity
$
822,728 $ 854,228
CHEMED CORPORATION
AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENT OF CASH
FLOWS (in thousands)(unaudited)
Three
Months Ended March 31,
2011 2010
Cash Flows from
Operating Activities Net income
$ 18,101 $ 19,358
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization
7,258 6,693 Noncash long-term
incentive compensation
2,595 - Provision for uncollectible
accounts receivable
2,111 2,472 Stock option expense
1,933 2,051 Amortization of discount on convertible notes
1,846 1,726 Provision for deferred income taxes
814
(2,282 ) Amortization of debt issuance costs
246 157
Changes in operating assets and
liabilities, excluding amounts acquired in business
combinations:
Decrease/(increase) in accounts receivable
17,923 (36,445 )
Increase in inventories
(239 ) (66 ) Decrease in
prepaid expenses
747 502 Decrease in accounts payable and
other current liabilities
(12,137 ) (381 ) Increase
in income taxes
9,739 13,955 Increase in other assets
(3,667 ) (1,672 ) Increase in other liabilities
3,227 2,724 Excess tax benefit on share-based compensation
(1,895 ) (1,135 ) Other uses
(61
) (6 ) Net cash provided by operating activities
48,541 7,651
Cash Flows from
Investing Activities Capital expenditures
(6,173
) (5,424 )
Proceeds from sales of property and
equipment
33 27 Other uses
(142 ) (157 )
Net cash used by investing activities
(6,282 )
(5,554 )
Cash Flows from Financing Activities
Purchases of treasury stock
(24,260 ) (2,516 )
Decrease in cash overdrafts payable
(8,310 ) (1,216 )
Proceeds from issuance of capital
stock
3,647 2,672 Dividends paid
(2,977 ) (2,739 )
Debt issuance costs
(2,708 ) - Excess tax benefit on
share-based compensation
1,895 1,135 Other sources
282 270 Net cash used by financing
activities
(32,431 ) (2,394 )
Increase/(Decrease) in Cash and Cash Equivalents
9,828 (297 ) Cash and cash equivalents at beginning of year
49,917 112,416 Cash and cash
equivalents at end of period
$ 59,745 $
112,119
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES CONSOLIDATING STATEMENT OF INCOME FOR THE
THREE MONTHS ENDED MARCH 31, 2011 AND 2010 (in
thousands)(unaudited)
Chemed VITAS Roto-Rooter
Corporate Consolidated
2011
Service revenues and sales $ 235,673 $ 95,245 $ -
$ 330,918 Cost of services provided and goods sold
184,300 53,158 - 237,458 Selling, general and administrative
expenses (a) 18,711 26,740 10,203 55,654 Depreciation 4,167 1,984
137 6,288 Amortization 483 132
355 970 Total costs and expenses
207,661 82,014 10,695
300,370 Income/(loss) from operations 28,012 13,231 (10,695
) 30,548 Interest expense (a) (48 ) (64 ) (3,132 ) (3,244 )
Intercompany interest income/(expense) 1,213 639 (1,852 ) -
Other income/(expense)—net
30 (9 ) 2,081 2,102
Income/(loss) before income taxes 29,207 13,797 (13,598 )
29,406 Income taxes (a) (11,082 ) (5,286 )
5,063 (11,305 ) Net income/(loss) $ 18,125 $
8,511 $ (8,535 ) $ 18,101
2010
Service revenues and sales $ 222,940 $ 85,873 $ -
$ 308,813 Cost of services provided and goods sold
172,093 47,044 - 219,137 Selling, general and administrative
expenses (b) 18,145 24,758 5,635 48,538 Depreciation 3,485 1,951 33
5,469 Amortization 771 123 330
1,224 Total costs and expenses 194,494
73,876 5,998 274,368
Income/(loss) from operations 28,446 11,997 (5,998 ) 34,445
Interest expense (b) (32 ) (68 ) (2,852 ) (2,952 ) Intercompany
interest income/(expense) 1,289 702 (1,991 ) -
Other income/(expense)—net (b)
(39 ) 10 215 186
Income/(loss) before income taxes 29,664 12,641 (10,626 ) 31,679
Income taxes (b) (11,226 ) (4,828 ) 3,733
(12,321 ) Net income/(loss) $ 18,438 $ 7,813
$ (6,893 ) $ 19,358 The "Footnotes to
Financial Statements" are integral parts of this financial
information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES CONSOLIDATING SUMMARY OF EBITDA FOR THE
THREE MONTHS ENDED MARCH 31, 2011 AND 2010 (in
thousands)(unaudited)
Chemed VITAS
Roto-Rooter Corporate Consolidated 2011
Net income/(loss) $ 18,125 $ 8,511 $ (8,535 ) $ 18,101
Add/(deduct): Interest expense 48 64 3,132 3,244 Income taxes
11,082 5,286 (5,063 ) 11,305 Depreciation 4,167 1,984 137 6,288
Amortization 483 132 355
970 EBITDA 33,905 15,977 (9,974 ) 39,908
Add/(deduct): Legal expenses of OIG investigation 511 - - 511
Acquisition expenses 64 6 - 70 Expenses of class action litigation
- 495 - 495 Long-term incentive compensation - - 3,012 3,012 Stock
option expense - - 1,933 1,933 Advertising cost adjustment (c) -
(250 ) - (250 ) Interest income (37 ) (7 ) (17 ) (61 ) Intercompany
interest income/(expense) (1,213 ) (639 )
1,852 - Adjusted EBITDA $ 33,230 $
15,582 $ (3,194 ) $ 45,618 2010 Net
income/(loss) $ 18,438 $ 7,813 $ (6,893 ) $ 19,358 Add/(deduct):
Interest expense 32 68 2,852 2,952 Income taxes 11,226 4,828 (3,733
) 12,321 Depreciation 3,485 1,951 33 5,469 Amortization 771
123 330 1,224
EBITDA 33,952 14,783 (7,411 ) 41,324 Add/(deduct): Legal expenses
of OIG investigation 160 - - 160 Stock option expense - - 2,051
2,051 Advertising cost adjustment (c) - (389 ) - (389 ) Interest
income (45 ) (2 ) (28 ) (75 ) Intercompany interest
income/(expense) (1,289 ) (702 ) 1,991
- Adjusted EBITDA $ 32,778 $ 13,690 $
(3,397 ) $ 43,071 The "Footnotes to Financial
Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME (in thousands,
except per share data)(unaudited)
Three Months Ended March 31,
2011 2010 Net income as reported
$ 18,101 $
19,358 Add/(deduct): After-tax cost of long-term incentive
compensation
1,880 - After-tax stock option expense
1,223 1,298
After-tax additional interest expense
resulting from the change in accounting for the conversion feature
of the convertible notes
1,132 1,047 After-tax cost of legal expenses of OIG
investigation
317 99 After-tax cost of expenses of class
action litigation
301 - After-tax cost of acquisition
expenses
44 - Adjusted net income
$
22,998 $ 21,802 Earnings Per Share As Reported
Net income
$ 0.86 $ 0.86 Average number of shares
outstanding
21,055 22,593 Diluted Earnings Per
Share As Reported Net income
$ 0.84 $ 0.84 Average
number of shares outstanding
21,568 23,021
Adjusted Earnings Per Share Net income
$
1.09 $ 0.96 Average number of shares outstanding
21,055 22,593 Adjusted Diluted Earnings Per Share Net
income
$ 1.07 $ 0.95 Average number of shares
outstanding
21,568 23,021 The
"Footnotes to Financial Statements" are integral parts of this
financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
Three Months Ended March 31, OPERATING STATISTICS
2011 2010
Net revenue ($000) (d) Homecare
$ 168,652 $ 157,226
Inpatient
27,386 26,291 Continuous care
38,625
37,674 Total before Medicare cap allowance
$
234,663 $ 221,191 Medicare cap allowance
1,010
1,749 Total
$ 235,673 $ 222,940
Net revenue as a percent of total before
Medicare cap allowance
Homecare
71.8 % 71.1 % Inpatient
11.7 11.9
Continuous care
16.5 17.0 Total before
Medicare cap allowance
100.0 100.0 Medicare cap allowance
0.4 0.8 Total
100.4 %
100.8 % Average daily census ("ADC") (days) Homecare
8,833 8,112 Nursing home
3,033 3,162
Routine homecare
11,866 11,274 Inpatient
450 442
Continuous care
603 606 Total
12,919 12,322 Total Admissions
15,798
14,844 Total Discharges
15,552 14,461 Average length of stay
(days)
78.9 75.8 Median length of stay (days)
13.0
13.0 ADC by major diagnosis Neurological
34.0 % 32.6
% Cancer
17.9 18.8 Cardio
11.8 11.9 Respiratory
6.7 6.6 Other
29.6 30.1 Total
100.0 % 100.0 % Admissions by major diagnosis
Neurological
19.5 % 18.6 % Cancer
31.7 33.5
Cardio
11.1 11.6 Respiratory
9.1 8.4 Other
28.6 27.9 Total
100.0 %
100.0 % Direct patient care margins (e) Routine homecare
51.5 % 51.3 % Inpatient
13.0 15.2 Continuous
care
20.5 20.7 Homecare margin drivers (dollars per patient
day) Labor costs
$ 55.38 $ 53.93 Drug costs
7.94 7.77 Home medical equipment
5.94 6.94 Medical
supplies
2.76 2.44 Inpatient margin drivers (dollars per
patient day) Labor costs
$ 306.66 $ 286.81 Continuous
care margin drivers (dollars per patient day) Labor costs
$
544.16 $ 526.47 Bad debt expense as a percent of revenues
0.6 % 1.0 % Accounts receivable -- Days of revenue
outstanding- excluding unapplied Medicare payments
55.3 43.4
Days of revenue outstanding- including unapplied Medicare payments
29.1 29.2 The "Footnotes to Financial Statements" are
integral parts of this financial information.
CHEMED
CORPORATION AND SUBSIDIARY COMPANIES FOOTNOTES TO FINANCIAL
STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2011 AND
2010 (unaudited)
(a)
Included in the results of operations for
the three months ended March 31, 2011, are the following
significant credits/(charges) which may not be indicative of
ongoing operations (in thousands):
VITAS
Roto-Rooter
Corporate Total Selling,
general and administrative expenses Legal expenses of OIG
investigation $ (511 ) $ - $ - $ (511 ) Acquisition expenses (64 )
(6 ) - (70 ) Expenses of class action litigation - (495 ) - (495 )
Long-term incentive compensation - - (3,012 ) (3,012 ) Stock option
expense - - (1,933 ) (1,933 ) Interest expense
Additional interest expense resulting from
the change in accounting for the conversion feature of the
convertible notes
- -
(1,790 )
(1,790 ) Pretax impact on earnings (575 )
(501 ) (6,735 ) (7,811 ) Income tax benefit/(charge) on the above
218 196
2,500 2,914
After-tax impact on earnings
$ (357
) $ (305 )
$ (4,235 ) $
(4,897 ) (b)
Included in the results of operations for
the three months ended March 31, 2010, are the following
significant credits/(charges) which may not be indicative of
ongoing operations (in thousands):
VITAS Corporate
Total Selling, general and administrative
expenses Legal expenses of OIG investigation $ (160 ) $ - $ (160 )
Stock option expense - (2,051 ) (2,051 ) Interest expense
Additional interest expense resulting from
the change in accounting for the conversion feature of the
convertible notes
- (1,655
) (1,655 ) Pretax
impact on earnings (160 ) (3,706 ) (3,866 ) Income tax
benefit/(charge) on the above
61
1,361 1,422
After-tax impact on earnings
$ (99
) $ (2,345 )
$ (2,444 ) (c)
Under Generally Accepted Accounting
Principles ("GAAP"), the Roto-Rooter segment expenses all
advertising, including the cost of telephone directories,
immediately upon the initial release of the advertising. Telephone
directories are generally in circulation 12 months. If a directory
is in circulation for a time period greater or less than 12 months,
the publisher adjusts the directory billing for the change in
billing period. The timing of when a telephone directory is
published can and does fluctuate significantly on a quarterly
basis. This "direct expensing" results in significant fluctuations
in quarterly advertising expense. In the first quarters of 2011 and
2010, GAAP advertising expense for Roto-Rooter totaled $5,918,000
and $5,735,000, respectively. If the expense of the telephone
directories were spread over the periods they are in circulation,
advertising expense for the first quarters of 2011 and 2010 would
total $6,168,000 and $6,124,000, respectively.
(d)
VITAS has 6 large (greater than 450 ADC),
21 medium (greater than 200 but less than 450 ADC) and 26 small
(less than 200 ADC) hospice programs. There is one program as of
March 31, 2011, with Medicare cap cushion of less than 10% for the
first six months of the 2011 Medicare cap year. Additionally, one
small program has a projected Medicare cap liability of $298,000
for the 2011 measurement period.
(e) Amounts exclude indirect patient care and administrative
costs, as well as Medicare Cap billing limitation.
Chemed (NYSE:CHE)
Historical Stock Chart
From Apr 2024 to May 2024
Chemed (NYSE:CHE)
Historical Stock Chart
From May 2023 to May 2024